Volume 2, Issue 3

COPD, Triple Therapy, GOLD, and COVID: State-of-the-ART Management (Early 2022)

In this issue:

Are all patients with COPD likely to benefit from LAMA+LABA+ICS triple therapy? The GOLD guidance has been updated. What’s new, what’s changed, and how should the revised recommendations be put into practice? Are people with COPD more susceptible to COVID infection? Or is inhaled corticosteroid therapy protective? What does the evidence say? 

Join us, as Dr. Nirupama Putcha from the Division of Pulmonology and Critical Care at Johns Hopkins University School of Medicine, explores these and other critical topics — in this issue of ePulmonology Review. 

Learning objectives:

  • Describe the evidence for recent and emerging treatments for COPD. 
  • Explain how GOLD guidelines translate into practice for patients with COPD. 


Nirupama Putcha, MD, MHS
Nirupama Putcha, MD, MHS

Assistant Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland

Program Directors:

Gregory B. Diette, MD

Professor of Medicine, Epidemiology and Environmental Health Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Christine Smith, RN, MSN

Senior Clinic Nurse Coordinator
Johns Hopkins Medicine
Baltimore, Maryland

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: March 30, 2022
Expiration date: March 29, 2024